Northern Financial Advisors Inc Sells 361 Shares of Colgate-Palmolive (NYSE:CL)

Northern Financial Advisors Inc lessened its position in Colgate-Palmolive (NYSE:CL) by 4.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 7,284 shares of the company’s stock after selling 361 shares during the period. Northern Financial Advisors Inc’s holdings in Colgate-Palmolive were worth $581,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Wealthcare Advisory Partners LLC lifted its stake in Colgate-Palmolive by 3.9% during the 4th quarter. Wealthcare Advisory Partners LLC now owns 3,404 shares of the company’s stock valued at $271,000 after acquiring an additional 127 shares during the period. &PARTNERS lifted its stake in shares of Colgate-Palmolive by 0.7% in the 4th quarter. &PARTNERS now owns 17,643 shares of the company’s stock valued at $1,406,000 after purchasing an additional 129 shares during the period. West Branch Capital LLC lifted its stake in shares of Colgate-Palmolive by 24.0% in the 4th quarter. West Branch Capital LLC now owns 682 shares of the company’s stock valued at $54,000 after purchasing an additional 132 shares during the period. First Foundation Advisors lifted its stake in shares of Colgate-Palmolive by 2.7% in the 3rd quarter. First Foundation Advisors now owns 5,226 shares of the company’s stock valued at $372,000 after purchasing an additional 136 shares during the period. Finally, Waldron Private Wealth LLC lifted its stake in shares of Colgate-Palmolive by 2.7% in the 3rd quarter. Waldron Private Wealth LLC now owns 5,361 shares of the company’s stock valued at $381,000 after purchasing an additional 140 shares during the period. Institutional investors own 80.41% of the company’s stock.

Colgate-Palmolive Stock Down 0.5 %

Shares of CL traded down $0.46 during mid-day trading on Wednesday, hitting $93.62. 3,284,846 shares of the company’s stock were exchanged, compared to its average volume of 4,649,866. The stock’s 50-day moving average is $88.64 and its 200-day moving average is $82.63. The company has a debt-to-equity ratio of 13.21, a quick ratio of 0.70 and a current ratio of 1.06. Colgate-Palmolive has a fifty-two week low of $67.62 and a fifty-two week high of $94.40. The company has a market cap of $76.81 billion, a price-to-earnings ratio of 29.77, a P/E/G ratio of 3.43 and a beta of 0.40.

Colgate-Palmolive (NYSE:CL) last released its earnings results on Friday, April 26th. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.82 by $0.04. Colgate-Palmolive had a net margin of 13.22% and a return on equity of 485.40%. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.96 billion. During the same period in the prior year, the firm earned $0.73 earnings per share. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Colgate-Palmolive will post 3.52 earnings per share for the current fiscal year.

Colgate-Palmolive Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 22nd will be paid a $0.50 dividend. This is a positive change from Colgate-Palmolive’s previous quarterly dividend of $0.48. This represents a $2.00 annualized dividend and a yield of 2.14%. The ex-dividend date of this dividend is Friday, April 19th. Colgate-Palmolive’s dividend payout ratio is currently 63.29%.

Insider Buying and Selling at Colgate-Palmolive

In other Colgate-Palmolive news, CEO Noel R. Wallace sold 50,000 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $83.15, for a total value of $4,157,500.00. Following the transaction, the chief executive officer now directly owns 274,179 shares in the company, valued at $22,797,983.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Noel R. Wallace sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $83.15, for a total transaction of $4,157,500.00. Following the transaction, the chief executive officer now directly owns 274,179 shares in the company, valued at $22,797,983.85. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jennifer Daniels sold 5,790 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $83.96, for a total value of $486,128.40. Following the sale, the insider now directly owns 63,236 shares of the company’s stock, valued at $5,309,294.56. The disclosure for this sale can be found here. Insiders have sold 159,048 shares of company stock worth $13,336,846 over the last three months. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on CL shares. UBS Group boosted their price target on shares of Colgate-Palmolive from $93.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, January 29th. Raymond James raised shares of Colgate-Palmolive from a “market perform” rating to an “outperform” rating and set a $91.00 price target for the company in a report on Monday, January 29th. Barclays boosted their price target on shares of Colgate-Palmolive from $84.00 to $85.00 and gave the stock an “equal weight” rating in a report on Tuesday, April 30th. TheStreet raised shares of Colgate-Palmolive from a “c+” rating to a “b+” rating in a report on Friday, January 26th. Finally, The Goldman Sachs Group assumed coverage on shares of Colgate-Palmolive in a report on Friday, March 1st. They set a “buy” rating and a $93.00 target price for the company. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, Colgate-Palmolive has an average rating of “Moderate Buy” and a consensus price target of $91.44.

Colgate-Palmolive Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.